1050 TREATING RELAPSE WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN AND AMANTADIN FOR EITHER 72 OR 48 WEEKS (IN PATIENTS WITH HCV-TYPE 1/3 INFECTION): RESULTS FROM THE TRELA-STUDY

✍ Scribed by Buggisch, P.; Zeuzem, S.; Teuber, G.; Möller, B.; Ehrhardt, A.; Gelbmann, C.; Encke, J.; Pohle, T.; Manns, M.P.; Stoll, S.; Berg, T.

• Book ID: 122592531
• Publisher: Elsevier Science
• Year: 2009
• Tongue: English
• Weight: 51 KB
• Volume: 50
• Category: Article
• ISSN: 0168-8278
• DOI: 10.1016/S0168-8278(09)61052-7